Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K4 | O95819 | 10/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.53 |
| ▸ | MINK1 | Q8N4C8 | 1/20 | 0.53 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.53 |
| ▸ | LRRK2 | Q5S007 | 5/20 | 0.51 |
| ▸ | USP7 | Q93009 | 2/20 | 0.48 |
| ▸ | FYN | P06241 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12518227 | 0.83 | CYP2A6 (0.62) | MAP4K4CYP1A2KCNH2MINK1TNIK | |
| SCHEMBL623725 | 0.82 | USP7 (0.69) | MAP4K4CYP1A2KCNH2MINK1TNIK | |
| SCHEMBL27961301 | 0.81 | MAP4K4 (0.70) | MAP4K4CYP1A2KCNH2MINK1TNIK | |
| SCHEMBL29973626 | 0.81 | MAP4K4 (0.70) | MAP4K4CYP1A2KCNH2MINK1TNIK | |
| SCHEMBL6069533 | 0.79 | MAP4K4 (0.64) | MAP4K4KCNH2MINK1TNIKFYN | |
| SCHEMBL29857960 | 0.79 | MAP4K4 (0.54) | MAP4K4LRRK2USP7FYNMEN1 | |
| SCHEMBL13968119 | 0.79 | MAP4K4 (0.54) | MAP4K4LRRK2USP7FYNMEN1 | |
| SCHEMBL4580922 | 0.79 | MAP4K4 (0.54) | MAP4K4LRRK2USP7FYNMEN1 | |
| SCHEMBL1091006 | 0.77 | MAP4K4 (0.76) | MAP4K4FYN | |
| SCHEMBL18372966 | 0.77 | RAB9A (0.60) | MAP4K4CYP1A2KCNH2MINK1TNIK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9682941-B2 | Substituted biphenyl analogues as dual inhibitors of aromatase and sulfatase | ESTRYX PHARMA LIMITED (GB) | 2017-06-20 | — | — | US | disclosed |
| US-20170001964-A1 | NEW SUBSTITUTED BIPHENYL ANALOGUES AS DUAL INHIBITORS OF AROMATASE AND SULFATASE | BEAUFOUR IPSEN TIANJIN PHARMACEUTICAL CO., LTD (CN) | 2017-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001964-A1 | NEW SUBSTITUTED BIPHENYL ANALOGUES AS DUAL INHIBITORS OF AROMATASE AND SULFATASE | CYP19A1, SULT2A1, STS | MAP4K4 3648/4885CYP1A2 22/4885KCNH2 4667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.